Profile | GDS2987 / GI_24307932-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | 0.3 | 1 |
GSM215253 | HMVEC_vehicle_rep3 | ||
GSM215254 | HMVEC_atorvastatin_rep1 | 3.5 | 10 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 3.2 | 5 |
GSM215294 | HMVEC_SLx2119_rep1 | 2.6 | 9 |
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | 5.3 | 9 |
GSM215297 | PASMC_vehicle_rep1 | 34.6 | 47 |
GSM215298 | PASMC_vehicle_rep2 | 30.4 | 43 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 20.8 | 35 |
GSM215312 | PASMC_atorvastatin_rep2 | 13.3 | 21 |
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | ||
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 6.4 | 13 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | ||
GSM215329 | PASMC_SLx2119_rep3 | 8.2 | 16 |
GSM215330 | Fibroblasts_vehicle_rep1 | ||
GSM215331 | Fibroblasts_vehicle_rep2 | 11.1 | 31 |
GSM215332 | Fibroblasts_vehicle_rep3 | 6.3 | 22 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | ||
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 0.1 | 0 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 7.7 | 25 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 10.6 | 29 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 5 | 15 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 16 | 41 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 24.1 | 51 |